Dabrafenib
BRAF V600E Mutation Present
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the BRAF V600E Mutation Present cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Onalespib National Cancer Institute (NCI) | Phase 1 | CC |
Ipilimumab National Cancer Institute (NCI) | Phase 1 | CC |
Cediranib National Cancer Institute (NCI) | Phase 1 | CC |
gsk1120212 National Cancer Institute (NCI) | Phase 1 | CC |
Nivolumab National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Dabrafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →